Tag
An indirect comparison shows tirzepatide significantly reduces major adverse cardiovascular events and mortality in type 2 diabetes patients, highlighting its potential for improving cardiovascular outcomes.
This study uses longitudinal modeling to compare tirzepatide and semaglutide’s effects on fasting glucose in type 2 diabetes, revealing tirzepatide’s superior control largely due to greater insulin-independent hepatic glucose production sup
A retrospective cohort study evaluating 1-year weight loss, glycaemic control, and safety outcomes among adults with obesity and type 2 diabetes treated with semaglutide, tirzepatide, or sleeve gastrectomy, highlighting higher efficacy with
Post hoc SURPASS-CVOT analysis found tirzepatide lowered a broad 6-component cardiorenal composite versus dulaglutide in high-risk patients with type 2 diabetes, with more gastrointestinal adverse events but similar overall safety.
In a SURMOUNT-1 post hoc analysis, tirzepatide improved multiple cardiovascular risk biomarkers over 72 weeks in obesity, with the largest and most consistent effects seen for inflammation, insulin resistance, adiposity-related markers, end
A 2026 study identifies a biologically distinct obesity subphenotype marked by fast gastric emptying, low GLP-1 synthesis, and substantially greater 6-month weight loss with tirzepatide.
In adults with early type 2 diabetes inadequately controlled on metformin, tirzepatide produced greater 2-year reductions in HbA1c, body weight, and waist circumference than intensified conventional care, with substantially higher rates of
In early type 2 diabetes uncontrolled on metformin, tirzepatide produced greater 2-year reductions in HbA1c, weight, and waist circumference than intensified conventional care, with more patients achieving normoglycemia.
In a pre-specified exploratory analysis of SURPASS-CVOT, tirzepatide reduced major kidney events versus dulaglutide in people with type 2 diabetes and cardiovascular disease, mainly by lowering new macroalbuminuria and slowing eGFR decline.
The SYNERGY-NASH trial demonstrates that Tirzepatide significantly improves MASH resolution and liver fibrosis. This effect is driven by substantial weight loss, improved glycemic control, and liver fat normalization, highlighting a transfo
A post hoc analysis of the SURMOUNT-4 trial reveals that withdrawing tirzepatide leads to significant weight regain and a proportional reversal of improvements in blood pressure, glycemic control, and lipid profiles, reinforcing the necessi
A Phase 2 trial demonstrates that tirzepatide significantly reduces body weight, HbA1c, and total daily insulin requirements in adults with type 1 diabetes and obesity, offering a promising therapeutic strategy for managing metabolic health
The SURPASS-CVOT trial confirms that tirzepatide is noninferior to dulaglutide for cardiovascular safety in high-risk type 2 diabetes patients. While superiority was not statistically reached, the study solidifies the cardiovascular profile
A post hoc analysis of the three‑year SURMOUNT‑1 trial found that once‑weekly tirzepatide (5–15 mg) produced dose‑dependent reductions in 10‑year predicted risks for ASCVD, heart failure, total CVD and progression to type 2 diabetes versus
This phase 3 study demonstrates that adding tirzepatide to basal insulin significantly improves glycemic control in Chinese patients with type 2 diabetes, with a manageable safety profile.
A large retrospective real‑world cohort (n=4241) of women with PCOS and overweight/obesity treated with tirzepatide experienced mean 18.8% weight loss at 10 months (90% lost ≥10%); digital engagement amplified outcomes. The data are promisi
This article critically compares the efficacy, safety, and long-term outcomes of tirzepatide, semaglutide, and liraglutide for the treatment of obesity based on recent Cochrane systematic reviews, highlighting differences in weight loss, ad
The phase 3 SURPASS-PEDS trial demonstrates that tirzepatide significantly improves glycaemic control and reduces BMI in children and adolescents with type 2 diabetes, with a safety profile consistent with adult studies.
In type 2 diabetes patients, tirzepatide treatment led to significant reductions in muscle fat infiltration and adaptive decreases in muscle volume over 52 weeks, suggesting beneficial effects on muscle health concurrent with weight loss.
The SUMMIT trial reveals that tirzepatide improves heart failure outcomes and quality of life in obese HFpEF patients with or without type 2 diabetes, despite attenuated weight loss in diabetic patients.
